Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Abbott Labs Reports Strong Q3 Earnings; Demand for Its Covid-19 Test Helps

Published 10/21/2020, 07:32 AM
Updated 10/21/2020, 07:32 AM
© Reuters.  Abbott Labs Earnings, Revenue Beat in Q3

© Reuters. Abbott Labs Earnings, Revenue Beat in Q3

Investing.com - Abbott Labs (NYSE:ABT) reported strong third-quarter earnings, helped by robust demand for the company's coronavirus diagnostic tests.

Abbott Labs announced earnings per share of $0.98, an increase of 16.7% from the previous year, on revenue of $8.85 billion, up 9.6%. Analysts polled by Investing.com expected EPS of $0.9 on revenue of $8.5 billion.

The company's stock rose 1.1% pre-market, but is still down 6% from the beginning of the year.

"Our strong results and increased guidance are a direct reflection of our ability to innovate and deliver despite challenging conditions," said Robert B. Ford, president and chief executive officer, Abbott. "Our new product pipeline continues to be highly productive, and we're well-positioned to finish the year with a lot of momentum."

The company's worldwide diagnostics sales increased 38.2% on a reported basis in the third quarter, helped by demand for Abbott's portfolio of Covid-19 diagnostics tests. In August, Abbott received FDA Emergency Use Authorization for its Covid-19 rapid test. Global Covid-19 testing-related sales were $881 million in the quarter.

Its worldwide medical devices sales increased 3.4%, while pharmaceuticals sales were less impressive, falling 9.3% in the third quarter.

Abbott projects full-year 2020 diluted earnings per share from continuing operations under GAAP of at least $2.35.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.